Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Tyligand Bio Files Hong Kong IPO with Phase II KRAS G12D Inhibitor TSN1611

Fineline Cube Jan 30, 2026
Company Deals

Genhouse Bio Files Hong Kong IPO with Phase II SHP2 Inhibitor GH21

Fineline Cube Jan 30, 2026
Company Deals

CSPC Pharma Signs $18.5B AstraZeneca Deal for Weight Management Portfolio

Fineline Cube Jan 30, 2026
Company Deals

Fosun Pharma Licenses HPV DNA Drug VGX-3100 from ApolloBio for Greater China

Fineline Cube Jan 29, 2026
Company Deals

Kanghua to Acquire NanoRibo in Phased Deal for mRNA Platform

Fineline Cube Jan 29, 2026
Policy / Regulatory

FDA Removes Suicide Warnings from GLP‑1 Drugs After Investigation Finds No Causal Link

Fineline Cube Jan 28, 2026
Company Drug

China Medical’s Opzelura Cream Gets NMPA Approval for Vitiligo

Fineline Cube Jan 30, 2026
Company Drug

Zhaoke Ophthalmology’s Yuvezzi Gets FDA Nod for Presbyopia

Fineline Cube Jan 30, 2026
Company Deals

Innovent’s Fortvita Stake Sale Sparks Controversy, Shares Plummet Nearly 13%

Fineline Cube Oct 30, 2024

Innovent Biologics, Inc. (HKG: 1801), headquartered in China, has announced a subscription agreement in which...

Company Medical Device

Sino Medical Reports Five-Year PIONEER Study Results for HT Supreme Stent System

Fineline Cube Oct 30, 2024

Sino Medical Sciences Technology Inc. (SHA: 688108), based in China, has announced the five-year follow-up...

Company Drug

Novartis Secures FDA Accelerated Approval for Scemblix in Newly Diagnosed CML Patients

Fineline Cube Oct 30, 2024

Swiss pharmaceutical giant Novartis (NYSE: NVS) announced that its drug Scemblix (asciminib) has received accelerated...

Company Deals

MGI Tech Partners with OncoDNA to Enhance Precision Oncology Solutions

Fineline Cube Oct 30, 2024

MGI Tech Co., Ltd., (SHA: 688114) a China-based leader in gene sequencing, announced a strategic...

Company Medical Device

Mindray Reports Q3 2024 Financials: International Revenues Surge Over 18% Amid Domestic Challenges

Fineline Cube Oct 30, 2024

Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (SHE: 300760) reported its Q3 2024 financial results, revealing...

Company

BeiGene CCO Yin Min Detained Amid Investigation; Company Affirms Compliance Standards

Fineline Cube Oct 30, 2024

On October 25, Yin Min, Chief Commercial Officer of BeiGene (NASDAQ: BGNE) Greater China, was...

Company Deals

Biogen Partners with Neomorph to Develop Molecular Glue Degraders for Alzheimer’s and Rare Diseases

Fineline Cube Oct 30, 2024

U.S.-based Biogen Inc. (NASDAQ: BIIB) has announced a research collaboration with Neomorph to jointly develop...

Company Drug

Yantai Dongcheng Pharma Secures FDA Fast-Track Designation for 177Lu-LNC1004 in Thyroid Cancer

Fineline Cube Oct 30, 2024

China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) has announced that it has received...

Company Drug

Sunshine Guojian Pharmaceutical Secures NMPA Approval for Clinical Trials of SSGJ-626 in Lupus Indications

Fineline Cube Oct 30, 2024

China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (SHA: 688336) has announced that it has received...

Company Drug

Zai Lab Reports Positive Phase III Results for KarXT, Showcasing Efficacy in Psychiatric Conditions

Fineline Cube Oct 30, 2024

China-based biotech Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) has announced encouraging topline results from...

Company Drug

Sun-Novo Pharmaceuticals Gets Green Light for CAR-T Therapy Clinical Trial in Lupus Treatment

Fineline Cube Oct 30, 2024

Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHA: 688621) has secured approval from China’s National Medical...

Company Deals

GSK Secures Global Rights to Chimagen Biosciences’ T Cell-Engager in $850 Million Deal

Fineline Cube Oct 30, 2024

UK pharmaceutical company GSK plc (NYSE: GSK) has entered into a licensing agreement with Chimagen...

Company

Fosun Pharmaceutical Reports Q3 2024 Revenue Growth and R&D Progress

Fineline Cube Oct 30, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has released its financial report...

Company

Shanghai Pharmaceuticals Reports Q3 2024 Revenue Growth, Strengthens Drug Pipeline

Fineline Cube Oct 30, 2024

China’s Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607) has announced its financial results for the...

Company Drug

Innovent Biologics’ Picankibart Shows 64.6% Skin Clearance in Phase II Psoriasis Study

Fineline Cube Oct 29, 2024

China-based Innovent Biologics, Inc. (HKG: 1801) has announced encouraging results from the multi-center, open Phase...

Company Drug

Livzon Pharmaceutical’s Leuprorelin Acetate Microspheres Passes China’s GQCE

Fineline Cube Oct 29, 2024

China’s Livzon Pharmaceutical Group Inc., (HKG: 1513, SHE: 000513) has announced that its leuprorelin acetate...

Company Drug

Xi’an Xintong Pharma’s Pradefavir Wins NMPA Nod for Chronic Hepatitis B Treatment

Fineline Cube Oct 29, 2024

The National Medical Products Administration (NMPA) has granted market approval for pradefavir, a Category 1...

Company Drug

Eli Lilly’s Mounjaro Approved in Hong Kong for Obesity and Type 2 Diabetes Treatment

Fineline Cube Oct 29, 2024

Eli Lilly & Co. (NYSE: LLY) has received market approval from Hong Kong’s Department of...

Company Drug

Clover Biopharmaceuticals Reports Strong Phase I Results for RSV Vaccine SCB-1019

Fineline Cube Oct 29, 2024

China-based Clover Biopharmaceuticals Ltd. (HKG: 2197) has announced encouraging additional immunogenicity and safety data from...

Company Drug

Merck and Moderna Launch Phase III Study for Individualized Neoantigen Therapy in Lung Cancer

Fineline Cube Oct 29, 2024

US pharmaceutical companies Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) and Moderna Inc. (NASDAQ:...

Posts pagination

1 … 227 228 229 … 617

Recent updates

  • China Medical’s Opzelura Cream Gets NMPA Approval for Vitiligo
  • Zhaoke Ophthalmology’s Yuvezzi Gets FDA Nod for Presbyopia
  • CSPC’s SYS 6055 CAR-T Gets NMPA Nod for Lymphoma Trials
  • AstraZeneca Commits $14.4B China Investment in Cell Therapy Push
  • Ascletis ASC40 Phase III Success in Acne Vulgaris
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

China Medical’s Opzelura Cream Gets NMPA Approval for Vitiligo

Company Drug

Zhaoke Ophthalmology’s Yuvezzi Gets FDA Nod for Presbyopia

Company Drug

CSPC’s SYS 6055 CAR-T Gets NMPA Nod for Lymphoma Trials

Company

AstraZeneca Commits $14.4B China Investment in Cell Therapy Push

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.